Regeneron won the first FDA approval under the agency’s national priority voucher framework with Otarmeni, an AAV-mediated gene therapy for a rare inherited hearing loss. The therapy is cleared for patients with hearing loss caused by variants in the otoferlin (OTOF) gene, and Regeneron said it plans to offer the treatment at no cost in the U.S. The approval also reflects how the voucher program is being used to accelerate access to therapies in rare pediatric disease settings. In early development, Otarmeni produced modest hearing gains, and the program’s clearance places the asset on a national commercialization track that differs from typical reimbursement timelines. Regeneron’s approval arrives amid heightened attention to how FDA’s voucher mechanics translate into concrete clinical access for patients, especially in ultra-rare conditions where trial sizes are small and evidence must be tightly framed.